Small Pharma: Psychedelic Mental Health Solutions
Offering real hope to millions around the globe
Small Pharma is a neuropharmaceutical company dedicated to unburdening the minds of millions of people around the world. They are developing innovative mental health solutions that offer real hope to millions, globally.
Further, Small Pharma is progressing the development of DMT-assisted therapy, using its proprietary synthetic formulation, SPL026, alongside psychotherapy. SPL026 is currently being trialed in its Phase I/IIa randomized controlled clinical trial for Major Depressive Disorder in the UK.
They are also progressing the preclinical development of their proprietary tryptamine analogues, SPL028 and SPL029, to assess their potential to deliver alternative treatment profiles for treating depression and other mental health disorders.
DMT is, in fact, a naturally occurring chemical with psychoactive properties found in plants and in the brain of mammals. Additionally, DMT is chemically similar to the neurotransmitter serotonin, which is involved in a variety of physiological functions in humans, including eating, sleep and mood regulation. Small Pharma has produced its own DMT-based product, SPL026, in line with good manufacturing practice guidelines laid down by agencies controlling authorisation and licensing of pharmaceutical products.
For more information on Small Pharma Inc. (TSX.V: DMT) please click the request investor info button.